[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546764":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":48,"centralContacts":52,"locations":62,"responsibleParty":93,"collaborators":96,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":41,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":41,"enrollmentInfo":107,"targetDuration":41,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":64,"whyStopped":41,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo group","PLACEBO_COMPARATOR","20 ml of normal saline is infused intravenously at 80 ml\u002Fh after anesthesia induction but before surgery.",[13],"Drug: Normal saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Dexmedetomidine group","EXPERIMENTAL","Dexmedetomidine 0.5 μg\u002Fkg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml\u002Fh after anesthesia induction but before surgery.",[19],"Drug: Dexmedetomidine",{"label":21,"type":16,"description":22,"interventionNames":23},"Esketamine group","Esketamine 0.25 mg\u002Fkg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml\u002Fh after anesthesia induction but before surgery.",[24],"Drug: Esketamine",{"label":26,"type":16,"description":27,"interventionNames":28},"Dexmedetomidine-esketamine group","Dexmedetomidine 0.5 μg\u002Fkg and esketamine 0.25 mg\u002Fkg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml\u002Fh after anesthesia induction but before surgery.",[29],"Drug: Combined dexmedetomidine-esketamine",[31,37,42,45],{"type":32,"name":33,"description":11,"armGroupLabels":34,"otherNames":35},"DRUG","Normal saline",[9],[36],"Placebo",{"type":32,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Dexmedetomidine","Dexmedetomidine 0.5 μg\u002Fkg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml\u002Fh after anesthesia induction but before surgery.",[15],null,{"type":32,"name":43,"description":22,"armGroupLabels":44,"otherNames":41},"Esketamine",[21],{"type":32,"name":46,"description":27,"armGroupLabels":47,"otherNames":41},"Combined dexmedetomidine-esketamine",[26],[49],{"name":50,"affiliation":5,"role":51},"Dong-Xin Wang, MD, PhD","PRINCIPAL_INVESTIGATOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":41,"email":57},"Rui Zhang, MD","CONTACT","+8618810662529","zhangrui_bjmu@163.com",{"name":59,"role":55,"phone":60,"phoneExt":41,"email":61},"Li Huaijin, MD","+8613488659162","crystal_35@163.com",[63,79],{"facility":5,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":71,"coordinates":72},"Point",[73,74],116.39723,39.9075,{"lat":74,"lon":73},[77],{"name":54,"role":55,"phone":78,"phoneExt":41,"email":57},"+86 18810662529",{"facility":80,"status":64,"city":81,"state":82,"zip":83,"country":68,"countryCode":69,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Peking University Shenzhen Hospital","Shenzhen","Guangdong","518036",{"type":71,"coordinates":85},[86,87],114.0683,22.54554,{"lat":87,"lon":86},[90],{"name":91,"role":55,"phone":41,"phoneExt":41,"email":92},"Tao Luo, MD","496855048@qq.com",{"type":51,"investigatorFullName":94,"investigatorTitle":95,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"Dong-Xin Wang","Professor",[97],{"name":80,"class":6},"100546764","phase-4-effect-of-dexmedetomidine-and-esketamine-on-catheter-related-bladder-discomfort-100546764",false,"NCT06399185","Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort","Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort in Patients Undergoing Transurethral Surgery: a 2 x 2 Factorial Randomized Trial","Inclusion Criteria:\n\n* Aged 18 years or above;\n* Scheduled to undergo transurethral bladder or prostate surgery (including transurethral resection of bladder tumor, transurethral resection of prostate, and transurethral thulium laser prostatectomy) under general anesthesia;\n* Required postoperative retention of a three-chamber urinary catheter.\n\nExclusion Criteria:\n\n* Indwelling urinary catheters or chronic analgesic therapy for ≥1 month before surgery;\n* Uncontrolled hypertension before surgery (resting ward systolic pressure \\>180 mmHg or diastolic pressure \\>110 mmHg);\n* Severe bradycardia (heart rate ≤50 beats per minute), sick sinus syndrome, or atrioventricular block of degree II or above without pacemaker, or having myocardial infarction, severe heart insufficiency (New York Heart Association class ≥3), or tachyarrhythmia within a year;\n* Preoperative history of schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or intracranial hypertension;\n* Preoperative history of hyperthyroidism and pheochromocytoma;\n* Inability to communicate due to coma, severe dementia, or language barrier before surgery;\n* Severe liver dysfunction (Child-Pugh grade C), severe renal dysfunction (receiving dialysis before surgery), or Amercian Society of Anesthesiologists classification ≥IV;\n* Scheduled admission to the intensive care unit with endotracheal intubation after surgery;\n* Other conditions that are considered unsuitable for study participation.","ALL","18 Years",{"count":108,"type":109},1740,"ESTIMATED","INTERVENTIONAL",[112],"PHASE4","Catheter-related bladder discomfort (CRBD) is common in patients awaking from general anesthesia with an urinary catheter. We suppose that that use of dexmedetomidine and\u002For esketamine during anesthesia may reduce the occurrence of CRBD. This 2x2 factorial randomized trial is designed to explore the effects of esketamine, dexmedetomidine, and their combination on the occurrence CRBD in patients undergoing transurethral urological surgery.",[115,116,38,43],"Urinary Catheter","Catheter-related Bladder Discomfort",[115,116,38,43],"2025-07-28",{"date":120,"type":121},"2025-07-31","ACTUAL",{"date":123,"type":121},"2024-06-06",{"date":125,"type":109},"2027-05",{"name":5,"class":6},2]